Literature DB >> 14625688

New insights into the metabolic and molecular basis for diabetic neuropathy.

A A F Sima1.   

Abstract

Diabetic polyneuropathy is the most common complication of diabetes mellitus. Several interactive pathogenetic mechanisms have been identified mainly in streptozotocin-induced diabetes in rats and have been ascribed to hyperglycemia. Over the last number of years it is becoming increasingly clear that diabetic neuropathy differs in type 1 and type 2 diabetes in humans and in murine models that more accurately mimic the human disorders. Beside hyperglycemia, attention is increasingly being paid to the pathogenetic roles of insulin and C-peptide deficiencies, particularly in type 1 diabetic neuropathy. There is now evidence to suggest that insulin and C-peptide deficiencies are mainly responsible for perturbations of neurotrophic factors and contribute to oxidative stress in diabetic nerve. This may also be true for apoptotic phenomena afflicting both the peripheral and central nervous systems in diabetes. The new data have lead to re-evaluations of pathogenetic components in this complex disorder, and their further exploration is likely to form a more refined basis for future therapeutic and preventive measures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625688     DOI: 10.1007/s00018-003-3084-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  34 in total

1.  Will C-peptide substitution make a difference in combating complications in insulin-deficient diabetes?

Authors:  Anders A F Sima
Journal:  Rev Diabet Stud       Date:  2004-08-10

2.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

3.  Age-dependent slowing of enteric axonal transport in insulin-resistant mice.

Authors:  Kathy J LePard; Joseph Cellini
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

4.  Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats.

Authors:  H Kamiya; W Zhang; A A F Sima
Journal:  Diabetologia       Date:  2006-09-20       Impact factor: 10.122

5.  Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy.

Authors:  L K Bhatt; Addepalli Veeranjaneyulu
Journal:  Neurol Sci       Date:  2010-03-06       Impact factor: 3.307

6.  Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes.

Authors:  Nizar Souayah; Joseph G Potian; Carmen C Garcia; Natalia Krivitskaya; Christine Boone; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

7.  Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

8.  Dynamic changes of neuroskeletal proteins in DRGs underlie impaired axonal maturation and progressive axonal degeneration in type 1 diabetes.

Authors:  Hideki Kamiya; Weixian Zhang; Anders A F Sima
Journal:  Exp Diabetes Res       Date:  2009-10-12

9.  Global transcriptional programs in peripheral nerve endoneurium and DRG are resistant to the onset of type 1 diabetic neuropathy in Ins2 mice.

Authors:  Anne-Sophie de Preux Charles; Valérie Verdier; Jennifer Zenker; Bastian Peter; Jean-Jacques Médard; Thierry Kuntzer; Jacques S Beckmann; Sven Bergmann; Roman Chrast
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

10.  Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat.

Authors:  Valentina A Carozzi; Alessia Chiorazzi; Annalisa Canta; Rena G Lapidus; Barbara S Slusher; Krystyna M Wozniak; Guido Cavaletti
Journal:  Neurotox Res       Date:  2009-09-15       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.